Age, Biography and Wiki
Laurent Levy was born on 1971 in Montreuil, France, is a French Scientist and Entrepreneur. Discover Laurent Levy's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 53 years old?
| Popular As |
N/A |
| Occupation |
CEO of Nanobiotix |
| Age |
53 years old |
| Zodiac Sign |
N/A |
| Born |
|
| Birthday |
|
| Birthplace |
Montreuil, France |
| Nationality |
France
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous CEO with the age 53 years old group.
Laurent Levy Height, Weight & Measurements
At 53 years old, Laurent Levy height not available right now. We will update Laurent Levy's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Laurent Levy Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Laurent Levy worth at the age of 53 years old? Laurent Levy’s income source is mostly from being a successful CEO. He is from France. We have estimated Laurent Levy's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
CEO |
Laurent Levy Social Network
Timeline
Laurent Levy (born 1971) is a French physical chemist, inventor, and pioneer of nanotechnology and nanomedicine.
He changed his area of study to biophysics then to physics and chemistry after two years, graduating with his bachelor's degree in 1994.
He then earned his master's degree (DEA) in physics of condensed matter from UPVI-ESPCI.
Laurent attended Paris VI and the CEA for doctoral studies in physical chemistry, specializing in nanomaterials.
His doctoral thesis centered on quantum confinement as it relates to magnetic semiconductors.
Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Prof. Paras N. Prasad at the Institute for Lasers, Photonics, and Biophotonics at SUNY Buffalo in the United States.
He is the co-founder of the global biotechnology company Nanobiotix, and has served as chief executive officer (CEO) since its inception in March 2003.
He also authored more than 35 international scientific publications and has applied for several patents.
Laurent Levy was born on the outskirts of northern-east Paris, France, in Montreuil.
After high school, Laurent went on to study biology at Pierre and Marie Curie University (Paris VI).
In 2003, Levy founded Nanobiotix to create a medical treatment using the techniques he developed at SUNY Buffalo.
Nanobiotix would build on his work to develop what is now known as NBTXR3, a first-in-class “radioenhancer” designed to significantly increase the efficacy of radiation therapy without increasing negative side effects associated with radiation.
In 2011, Nanobiotix treated its first patient using NBTXR3.
To advocate for nanomedical development, Levy joined the European Technology Platform Nanomedicine (ETPN) in 2012 and was elected Vice President.
Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies.
Levy also helped to establish the ETPN's Nanomedicine Translation Hub, which advises SMEs, Startups, Academics and Inventors on how to bring their nanomedicine projects to the market.
In 2015 Levy joined the board of biotech startup Valbiotis, the first company to register a nutraceutical based on clinical findings.
The company develops nutraceutical products for the prevention of diabetes in pre-diabetics.
In 2018 the results of a phase III clinical trial established that this new type of product could work in humans.
Levy helped take Valbiotis public in 2018.
In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall.
In 2019, Levy co-founded the biotechnology company Curadigm as a spin-off from Nanobiotix.
Curadigm's lead technology is a nanoprimer that affects liver function, reducing its ability to filter out drugs, making drug delivery more efficacious.
As Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the European Union.
